Novabay Pharmaceuticals Stock Performance
| NBY Stock | USD 0.54 0.02 3.85% |
NovaBay Pharmaceuticals holds a performance score of 4 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 4.94, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NovaBay Pharmaceuticals will likely underperform. Use NovaBay Pharmaceuticals sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on NovaBay Pharmaceuticals.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NovaBay Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental drivers, NovaBay Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.339 | Last Split Factor 1:35 | Dividend Date 2025-09-29 | Ex Dividend Date 2025-09-30 | Last Split Date 2024-05-31 |
1 | NovaBay Pharmaceuticals Shares Gap Down - Heres Why - MarketBeat | 12/23/2025 |
2 | NovaBay Pharmaceuticals Shares Down 6.8 percent - Should You Sell - MarketBeat | 12/29/2025 |
3 | NovaBay Pharmaceuticals Stock Price Up 14.2 percent - Should You Buy - MarketBeat | 01/05/2026 |
4 | Novabay Pharmaceuticals stock hits 52-week high at 11.49 USD By Investing.com - Investing.com India | 01/09/2026 |
5 | NovaBay Pharmaceuticals Stock Why Shares Exploded 103 percent on Friday | 01/12/2026 |
6 | NovaBay Pharma Secures Crypto-Focused Financing, Shifts Strategy - TipRanks | 01/16/2026 |
7 | NovaBay Pharmaceuticals Stock Price Down 14.3 percent - Should You Sell - MarketBeat | 01/21/2026 |
8 | Acquisition by David Lazar of 6388000 shares of NovaBay Pharmaceuticals subject to Rule 16b-3 | 01/29/2026 |
9 | NovaBay Pharma Schedules Special Shareholder Meeting on Warrants - TipRanks | 01/30/2026 |
| Begin Period Cash Flow | 2.9 M | |
| Total Cashflows From Investing Activities | 1.1 M |
NovaBay Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 99.00 in NovaBay Pharmaceuticals on November 20, 2025 and sell it today you would lose (45.00) from holding NovaBay Pharmaceuticals or give up 45.45% of portfolio value over 90 days. NovaBay Pharmaceuticals is generating 1.4254% of daily returns assuming volatility of 23.7615% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than NovaBay, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
NovaBay Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of NovaBay Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.54 | 90 days | 0.54 | about 78.83 |
Based on a normal probability distribution, the odds of NovaBay Pharmaceuticals to move above the current price in 90 days from now is about 78.83 (This NovaBay Pharmaceuticals probability density function shows the probability of NovaBay Stock to fall within a particular range of prices over 90 days) .
NovaBay Pharmaceuticals Price Density |
| Price |
Predictive Modules for NovaBay Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NovaBay Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.NovaBay Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NovaBay Pharmaceuticals is not an exception. The market had few large corrections towards the NovaBay Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NovaBay Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NovaBay Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.94 | |
β | Beta against Dow Jones | 4.94 | |
σ | Overall volatility | 4.11 | |
Ir | Information ratio | 0.05 |
NovaBay Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NovaBay Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NovaBay Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| NovaBay Pharmaceuticals is way too risky over 90 days horizon | |
| NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock | |
| NovaBay Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| NovaBay Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 9.78 M. Reported Net Loss for the year was (7.21 M) with profit before taxes, overhead, and interest of 6.52 M. | |
| NovaBay Pharmaceuticals has about 430 K in cash with (5.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07. | |
| Roughly 92.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: NovaBay Pharma Schedules Special Shareholder Meeting on Warrants - TipRanks |
NovaBay Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NovaBay Stock often depends not only on the future outlook of the current and potential NovaBay Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NovaBay Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.4 M | |
| Cash And Short Term Investments | 430 K |
NovaBay Pharmaceuticals Fundamentals Growth
NovaBay Stock prices reflect investors' perceptions of the future prospects and financial health of NovaBay Pharmaceuticals, and NovaBay Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NovaBay Stock performance.
| Return On Equity | -5.16 | ||||
| Return On Asset | -0.87 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | (2.24) % | ||||
| Current Valuation | 70.37 M | ||||
| Shares Outstanding | 129.61 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 2.17 X | ||||
| Price To Sales | 6.59 X | ||||
| Revenue | 9.78 M | ||||
| Gross Profit | 6.52 M | ||||
| EBITDA | (5.92 M) | ||||
| Net Income | (7.21 M) | ||||
| Cash And Equivalents | 430 K | ||||
| Cash Per Share | 0.07 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | (0.45) X | ||||
| Cash Flow From Operations | (5.18 M) | ||||
| Earnings Per Share | 5.16 X | ||||
| Market Capitalization | 67.91 M | ||||
| Total Asset | 3.42 M | ||||
| Retained Earnings | (183.46 M) | ||||
| Working Capital | (908 K) | ||||
| Current Asset | 4.53 M | ||||
| Current Liabilities | 4.63 M | ||||
About NovaBay Pharmaceuticals Performance
Evaluating NovaBay Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NovaBay Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NovaBay Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 97.31 | 92.44 | |
| Return On Tangible Assets | (2.43) | (2.31) | |
| Return On Capital Employed | (11.58) | (11.00) | |
| Return On Assets | (2.43) | (2.31) | |
| Return On Equity | 50.39 | 52.91 |
Things to note about NovaBay Pharmaceuticals performance evaluation
Checking the ongoing alerts about NovaBay Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NovaBay Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NovaBay Pharmaceuticals is way too risky over 90 days horizon | |
| NovaBay Pharmaceuticals has some characteristics of a very speculative penny stock | |
| NovaBay Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| NovaBay Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 9.78 M. Reported Net Loss for the year was (7.21 M) with profit before taxes, overhead, and interest of 6.52 M. | |
| NovaBay Pharmaceuticals has about 430 K in cash with (5.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07. | |
| Roughly 92.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: NovaBay Pharma Schedules Special Shareholder Meeting on Warrants - TipRanks |
- Analyzing NovaBay Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NovaBay Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining NovaBay Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NovaBay Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NovaBay Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NovaBay Pharmaceuticals' stock. These opinions can provide insight into NovaBay Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.